Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 965080222 | 9650802 | 22 | F | 20140113 | 20160919 | 20131029 | 20160920 | EXP | CA-ROCHE-1262991 | ROCHE | 73.21 | YR | F | Y | 56.00000 | KG | 20160920 | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 965080222 | 9650802 | 1 | PS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B2014162,B2038B093,B2024B203,B20278 | 125276 | 504 | MG | SOLUTION FOR INFUSION | |||||||
| 965080222 | 9650802 | 2 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B2014162,B2038B093,B2024B203,B20278 | 125276 | 496 | MG | SOLUTION FOR INFUSION | |||||||
| 965080222 | 9650802 | 3 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B2014162,B2038B093,B2024B203,B20278 | 125276 | 480 | MG | SOLUTION FOR INFUSION | |||||||
| 965080222 | 9650802 | 4 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B2014162,B2038B093,B2024B203,B20278 | 125276 | 440 | MG | SOLUTION FOR INFUSION | |||||||
| 965080222 | 9650802 | 5 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B2014162,B2038B093,B2024B203,B20278 | 125276 | 472 | MG | SOLUTION FOR INFUSION | |||||||
| 965080222 | 9650802 | 6 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B2014162,B2038B093,B2024B203,B20278 | 125276 | 464 | MG | SOLUTION FOR INFUSION | |||||||
| 965080222 | 9650802 | 7 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B2014162,B2038B093,B2024B203,B20278 | 125276 | 456 | MG | SOLUTION FOR INFUSION | |||||||
| 965080222 | 9650802 | 8 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B2014162,B2038B093,B2024B203,B20278 | 125276 | 448 | MG | SOLUTION FOR INFUSION | |||||||
| 965080222 | 9650802 | 9 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B2014162,B2038B093,B2024B203,B20278 | 125276 | 456 | MG | SOLUTION FOR INFUSION | |||||||
| 965080222 | 9650802 | 10 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B2014162,B2038B093,B2024B203,B20278 | 125276 | 440 | MG | SOLUTION FOR INFUSION | |||||||
| 965080222 | 9650802 | 11 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | B2014162,B2038B093,B2024B203,B20278 | 125276 | 443 | MG | SOLUTION FOR INFUSION | /wk | ||||||
| 965080222 | 9650802 | 12 | SS | ACCUPRIL | QUINAPRIL HYDROCHLORIDE | 1 | Oral | Y | 0 | ||||||||||
| 965080222 | 9650802 | 13 | C | RESTASIS | CYCLOSPORINE | 1 | Unknown | 0 | |||||||||||
| 965080222 | 9650802 | 14 | C | AVAMYS | FLUTICASONE FUROATE | 1 | 0 | ||||||||||||
| 965080222 | 9650802 | 15 | C | PATADAY | OLOPATADINE HYDROCHLORIDE | 1 | Unknown | AS REQUIRED | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 965080222 | 9650802 | 1 | Rheumatoid arthritis |
| 965080222 | 9650802 | 12 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 965080222 | 9650802 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 965080222 | 9650802 | Abdominal pain upper | |
| 965080222 | 9650802 | Arthralgia | |
| 965080222 | 9650802 | Back pain | |
| 965080222 | 9650802 | Blood cholesterol increased | |
| 965080222 | 9650802 | Blood pressure increased | |
| 965080222 | 9650802 | Diarrhoea | |
| 965080222 | 9650802 | Drug ineffective | |
| 965080222 | 9650802 | Dry eye | |
| 965080222 | 9650802 | Eye pruritus | |
| 965080222 | 9650802 | Fatigue | |
| 965080222 | 9650802 | Foot deformity | |
| 965080222 | 9650802 | Headache | |
| 965080222 | 9650802 | Heart rate decreased | |
| 965080222 | 9650802 | Hypotension | |
| 965080222 | 9650802 | Infusion related reaction | |
| 965080222 | 9650802 | Muscle spasms | |
| 965080222 | 9650802 | Musculoskeletal pain | |
| 965080222 | 9650802 | Ocular hyperaemia | |
| 965080222 | 9650802 | Pain | |
| 965080222 | 9650802 | Pain in extremity | |
| 965080222 | 9650802 | Sciatica | |
| 965080222 | 9650802 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 965080222 | 9650802 | 1 | 20130718 | 0 | ||
| 965080222 | 9650802 | 2 | 20130813 | 0 | ||
| 965080222 | 9650802 | 3 | 20140113 | 0 | ||
| 965080222 | 9650802 | 4 | 20140605 | 0 | ||
| 965080222 | 9650802 | 5 | 20140703 | 0 | ||
| 965080222 | 9650802 | 6 | 20140728 | 0 | ||
| 965080222 | 9650802 | 7 | 20141023 | 0 | ||
| 965080222 | 9650802 | 8 | 20141216 | 0 | ||
| 965080222 | 9650802 | 9 | 20150127 | 0 | ||
| 965080222 | 9650802 | 10 | 20150507 | 0 | ||
| 965080222 | 9650802 | 11 | 20160201 | 20160711 | 0 | |
| 965080222 | 9650802 | 12 | 201309 | 0 |